Table 2.

Survival analysis of nivolumab treatment in patients with advanced/relapsed hepatitis B virus-related hepatocellular carcinoma.

	Parameter	Univariate analysis		Multivariate analysis
		HR (95% CI)	p	HR (95% CI)	p
PFS	Gender (Male vs. Female)	0.50 (0.14–1.80)	0.286	0.35 (0.05–2.50)	0.294
	Age (≥63 vs. <63)	0.19 (0.04–0.84)	0.029	0.12 (0.02–0.94)	0.044
	HBV-DNA (≥215 vs. <215)	2.24 (0.84–5.93)	0.105	1.03 (0.34–3.07)	0.964
	AFP (≥40 vs. <40)	1.09 (0.42–2.84)	0.863	3.72 (0.48–28.54)	0.207
	Child-Pugh (A vs. B)	0.43 (0.16–1.13)	0.085	4.12 (0.76–22.40)	0.101
	ECOG (≥2 vs. <2)	2.87 (0.95–8.67)	0.061	6.88 (0.94–50.22)	0.057
	Hepatectomy (Yes vs. No)	2.85 (1.01–8.03)	0.048	13.10 (1.92–89.35)	0.009
	TACE (Yes vs. No)	0.42 (0.16–1.13)	0.085	0.09 (0.02–0.46)	0.004
	Number of nivolumab cycles (≥9 vs. <9)	0.28 (0.10–0.80)	0.017	0.09 (0.01–0.56)	0.010
	Single dose of nivolumab (≥200 vs. <200)	1.97 (0.45–8.65)	0.371	0.57 (0.06–5.42)	0.624
	Combined treatment (targeted therapy vs. chemo)	0.60 (0.21–1.74)	0.345	0.54 (0.11–2.61)	0.446
OS	Gender (Male vs. Female)	0.68 (0.14–3.21)	0.625	1.99 (0.27–10.31)	0.424
	Age (≥63 vs. <63)	0.17 (0.02–1.31)	0.089	0.16 (0.02–1.35)	0.092
	HBV-DNA (≥215 vs. <215)	2.21 (0.76–6.42)	0.143	1.62 (0.52–5.01)	0.406
	AFP (≥40 vs. <40)	1.60 (0.54–4.82)	0.398	2.33 (0.56–9.78)	0.248
	Child-Pugh (A vs. B)	0.21 (0.06–0.74)	0.015	0.20 (0.05–0.81)	0.024
	ECOG (≥2 vs. <2)	2.72 (0.77–9.69)	0.122	0.66 (0.13–3.32)	0.618
	Hepatectomy (Yes vs. No)	1.87 (0.61–5.81)	0.276	2.17 (0.59–7.95)	0.241
	TACE (Yes vs. No)	0.55 (0.19–1.61)	0.273	1.19 (0.30–4.75)	0.802
	Number of nivolumab cycles (≥9 vs. <9)	0.26 (0.07–0.93)	0.039	0.44 (0.12–1.61)	0.214
	Single dose of nivolumab (≥200 vs. <200)	4.21 (0.54–32.96)	0.171	0.80 (0.06–10.35)	0.863
	Combined treatment (targeted therapy vs. chemo)	1.02 (0.31–3.32)	0.970	1.03 (0.23–4.70)	0.968